Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland

European Journal of Human Genetics

Volumn 9, Issue 6, 2001, Pages 404-408

  Niemimaa, Marko ^a   Suonpää, Mikko ^b   Perheentupa, Antti ^a   Seppälä, Maija ^b   Heinonen, Seppo ^c   Laitinen, Päivi ^a   Ruokonen, Aimo ^a   Ryynänen, Markku ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b Wallac Oy   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Down's syndrome; First trimester trisomy screening; Maternal serum screening; Prenatal diagnosis

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; BIOCHEMISTRY; CALCULATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOWN SYNDROME; FEMALE; FETUS; FETUS ECHOGRAPHY; FINLAND; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL SERUM; MEASUREMENT; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; RISK; SECOND TRIMESTER PREGNANCY; TRISOMY; TRISOMY 21; ULTRASOUND;

ADULT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; FINLAND; HUMANS; MOTHERS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 0034977305     PISSN: 10184813     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5200655     Document Type: Article

References (24)

1. Ultrasonographically detectable markers of fetal chromosomal abnormalities
2. First trimester diagnosis of nuchal anomalies: Significance and fetal outcome
3. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation
4. Increased nuchal translucency as a marker for fetal chromosomal defects
5. First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome
6. First trimester biochemical screening for trisomy 21: The role of free beta-hCG alpha fetoprotein and pregnancy associated plasma protein A
7. First-trimester Down syndrome screening: Free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A
8. Screening of maternal serum for fetal Down's syndrome in the first trimester
9. First trimester aneuploidy screening using nuchal translucency, free beta human chorionic gonadotrophin and maternal age
10. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy
11. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities
12. First-trimester screening for fetal aneuploidy: Biochemistry and nuchal translucency
13. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome
14. First trimester screening for Down's syndrome using maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal translucency thickness
15. First-trimester screening for Down syndrome using nuchal translucency measurement with free beta-hCG and PAPP-A between 10 and 13 weeks of pregnancy-the combined test
16. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency
17. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy associated plasma protein-A
18. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency
19. One stop clinic for assessment of risk for fetal anomalies: A report of the first year of prospective screening for chromosomal anomalies in the first trimester
20. The autodelfia™ assay for pregnancy associated plasma protein A (PAPP-A) to be used in the screening for Down syndrome in the first trimester of pregnancy
21. Maternal age- and gestation-specific risk for trisomy 21
22. Fetal loss in Down syndrome pregnancies
23. Screening for Down's syndrome: The effect of test date on the detection rate